NCT07919678ClinicalTrials.gov
A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY (VESPER-OA 1)
In breve
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of…
Fase 3656 partecipanti ricercati40 centri2 paesi
Categorie
Registrato in 1 registro
- ClinicalTrials.govNCT07919678Apri questa scheda su ClinicalTrials.govSincronizzato 2 settimane fa
Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.
Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.
Ti interessa questo studio?
Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 10 days after the recorded start)First posted 2026-11-05; recorded start 2026-10-26
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 635 other studies in this databaseCounted from the lead sponsor named in the record (Pfizer)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 3 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 40 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 656 participants (target), run at 40 sites, across 2 countries.
How this score is built
- Enrolment28/40
656 participants (target)
- Site count19/25
40 sites
- Country count7/15
2 countries
- Planned duration7/10
Planned over about 24 months
- Sponsor scale10/10
Pfizer has led 630 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Sintesi
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.
Patologie
- Obesity
- Overweight
- Osteoarthritis of the Knee
Idoneità
| Sesso | Tutti |
|---|---|
| Età | 18 Years – Nessun massimo |
| Volontari sani | No |
Idoneità come riportata nel registro
Idoneità in frasi semplici
I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.
Disegno dello studio
| Tipo di studio | Interventistico |
|---|---|
| Fase | Fase 3 |
| Assegnazione | Randomizzata |
| Modello di intervento | PARALLEL |
| Finalità principale | TREATMENT |
| Mascheramento | QUADRUPLE (4) |
| Arruolamento | 656 partecipanti ricercati |
Sponsor e collaboratori
- Pfizer Sponsor
Bracci e interventi
- PlaceboPLACEBO_COMPARATOR
Participants will receive placebo as subcutaneous injection
- Arm 1: Berobenatide Once MonthlyEXPERIMENTAL
Participants will receive berobenatide by subcutaneous injection.
- Arm 2: Berobenatide Once MonthlyEXPERIMENTAL
Participants receive berobenatide by subcutaneous injection.
- Arm 3: Berobenatide Once MonthlyEXPERIMENTAL
Participants receive berobenatide by subcutaneous injection.
Interventi
- Farmaco Berobenatide
Subcutaneous Injection
- Altro Placebo
Subcutaneous Injection
Esiti misurati
Esito primario
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score
Orizzonte temporale Baseline and Week 52
Esito secondario
Percent change from baseline in Body Weight
Orizzonte temporale Baseline and Week 52
Esito secondario
Change From Baseline in High-Sensitivity C-Reactive Protein
Orizzonte temporale Baseline and Week 52
Esito secondario
Change from baseline in WOMAC Physical Function Subscale score
Orizzonte temporale Baseline and Week 52
Esito secondario
Percentage of participants with ≥50% reduction in the WOMAC pain subscale score
Orizzonte temporale Baseline and Week 52
Esito secondario
Percentage of participants with ≥30% reduction in the WOMAC pain subscale score
Orizzonte temporale Baseline and Week 52
Esito secondario
Proportion of participants with utilization of protocol specified pain medication during the washout period
Orizzonte temporale Baseline and Week 52
Esito secondario
Amount of protocol specified pain medication during the washout period
Orizzonte temporale Baseline and Week 52
Esito secondario
Change from baseline in WOMAC stiffness score
Orizzonte temporale Baseline and Week 52
Esito secondario
Change from baseline in WOMAC total score
Orizzonte temporale Baseline and Week 52
Esito secondario
Proportion of participants achieving ≥50% reduction in the WOMAC physical function subscale score
Orizzonte temporale Baseline and Week 52
Esito secondario
Proportion of participants meeting OMERACT-OARSI
Orizzonte temporale Baseline and Week 52
Esito secondario
Change from baseline in Average Pain Intensity-Numerical Rating Score
Orizzonte temporale Baseline and Week 52
Esito secondario
Change from baseline in Worst Pain Intensity -Numerical Rating Score
Orizzonte temporale Baseline and Week 52
Esito secondario
Change from baseline in SF-36 domain scales and component summary scales
Orizzonte temporale Baseline and Week 52
Esito secondario
Change from baseline in Body Weight
Orizzonte temporale Baseline and Week 52
Esito secondario
Change from Baseline in Body Mass Index
Orizzonte temporale Baseline and Week 52
Esito secondario
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Orizzonte temporale Baseline and Week 52
Esito secondario
Number of Participants with Serious Adverse Events (SAE)
Orizzonte temporale Baseline and Week 52
Esito secondario
Number of Participants with AE leading to permanent discontinuation from study intervention or study
Orizzonte temporale Baseline and Week 52
Esito secondario
Number of Participants with Adverse Events of Special Interest (AESI)
Orizzonte temporale Baseline and Week 52
Esito secondario
Number of Participants with Clinical laboratory abnormalities
Orizzonte temporale Baseline and Week 52
Esito secondario
Change from baseline in timed walking distance at Week 52
Orizzonte temporale Baseline and Week 52
Esito secondario
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA related physical function
Orizzonte temporale Baseline and Week 52
Esito secondario
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA pain
Orizzonte temporale Baseline and Week 52
Esito secondario
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) for knee-OA related physical function
Orizzonte temporale Baseline and Week 52
Esito secondario
Percentage of Participants Reporting Improvement in Patient Global Impression of Change PGI-C for knee-OA pain
Orizzonte temporale Baseline and Week 52
Esito secondario
Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score
Orizzonte temporale Baseline and Week 52
Esito secondario
Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score
Orizzonte temporale Baseline and Week 52
Esito secondario
Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score
Orizzonte temporale Baseline and Week 52
Esito secondario
Change From Baseline in WPAI:GH Work productivity loss score
Orizzonte temporale Baseline and Week 52
Esito secondario
Change From Baseline in WPAI:GH Activity impairment score
Orizzonte temporale Baseline and Week 52
Esito secondario
Change From Baseline in Systolic Blood Pressure (SBP)
Orizzonte temporale Baseline and Week 52
Esito secondario
Change From Baseline in Diastolic Blood Pressure (DBP)
Orizzonte temporale Baseline and Week 52
Esito secondario
Change From Baseline in Total Cholesterol
Orizzonte temporale Baseline and Week 52
Esito secondario
Change From Baseline in High-density lipoprotein cholesterol (HDL-C)
Orizzonte temporale Baseline and Week 52
Esito secondario
Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)
Orizzonte temporale Baseline and Week 52
Esito secondario
Change from baseline in Non-HDL Cholesterol
Orizzonte temporale Baseline and Week 52
Esito secondario
Change from baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol
Orizzonte temporale Baseline and Week 52
Esito secondario
Change from baseline in Triglycerides
Orizzonte temporale Baseline and Week 52
Date
| Data di inizio | 26 ottobre 2026 (effettiva) |
|---|---|
| Conclusione primaria | 22 agosto 2028 (stimata) |
| Conclusione | 10 ottobre 2028 (stimata) |
| Prima pubblicazione | 5 novembre 2026 (effettiva) |
| Ultimo aggiornamento | 5 novembre 2026 |
| Risultati pubblicati | Non indicato nella scheda del registro |
| Stato verificato l'ultima volta | ottobre 2026 |
«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.
Centri
7 centri stanno reclutando
Canada
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Bluewater Clinical Research Group Inc. | Sarnia | Ontario | Non ancora in reclutamento |
United States
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Albuquerque Clinical Trials, Inc. | Albuquerque | New Mexico | Non ancora in reclutamento |
| Charlottesville Medical Research Center, LLC | Charlottesville | Virginia | Non ancora in reclutamento |
| Northwestern University Feinberg School Of Medicine | Chicago | Illinois | Non ancora in reclutamento |
| Great Lakes Clinical Trials, LLC dba Flourish Research | Chicago | Illinois | Non ancora in reclutamento |
| Northwestern Medicine | Chicago | Illinois | Non ancora in reclutamento |
| Northwestern Memorial Hospital, Diagnostic Testing Center (Phlebotomy/EKG) | Chicago | Illinois | Non ancora in reclutamento |
| Northwestern Memorial Hospital, Investigational Drug Service | Chicago | Illinois | Non ancora in reclutamento |
| Clinical Research of West Florida, Inc. | Clearwater | Florida | Non ancora in reclutamento |
| Skylight Health Research | Colorado Springs | Colorado | Non ancora in reclutamento |
| Mercy Family Clinic | Dallas | Texas | Non ancora in reclutamento |
| Universal Axon Clinical Research LLC | Doral | Florida | In reclutamento |
| Altoona Center For Clinical Research | Duncansville | Pennsylvania | In reclutamento |
| Headlands Research California, LLC | Escondido | California | Non ancora in reclutamento |
| Profound Research LLC | Farmington Hills | Michigan | In reclutamento |
| Cedar Health Research | Fort Worth | Texas | Non ancora in reclutamento |
| Novant Health Granite Quarry Internal Medicine (knee x-ray) | Granite Quarry | North Carolina | Non ancora in reclutamento |
| BRCR Global Louisiana | Gretna | Louisiana | Non ancora in reclutamento |
| JCCT-JUNO NW Houston | Houston | Texas | Non ancora in reclutamento |
| Westside Center for Clinical Research | Jacksonville | Florida | Non ancora in reclutamento |
| Activian Clinical Research | Kingwood | Texas | Non ancora in reclutamento |
| Renstar Medical Research | Lady Lake | Florida | Non ancora in reclutamento |
| Monroe Biomedical Research | Monroe | North Carolina | In reclutamento |
| AMR Clinical | Norman | Oklahoma | Non ancora in reclutamento |
| Renstar Medical Research | Ocala | Florida | Non ancora in reclutamento |
| Prospective Research Innovations Inc. | Rancho Cucamonga | California | Non ancora in reclutamento |
| Accellacare - Salisbury | Salisbury | North Carolina | Non ancora in reclutamento |
| Consano Clinical Research, LLC | Shavano Park | Texas | Non ancora in reclutamento |
| Revive Research Institute, Inc. | Sterling Heights | Michigan | In reclutamento |
| Clinical Research Atlanta | Stockbridge | Georgia | Non ancora in reclutamento |
| Clinical Research of West Florida, Inc. | Tampa | Florida | Non ancora in reclutamento |
| AMR Clinical | Tempe | Arizona | Non ancora in reclutamento |
| DM Clinical Research | Tomball | Texas | Non ancora in reclutamento |
| Solace Clinical Research | Tustin | California | Non ancora in reclutamento |
| Velocity Clinical Research, Waco | Waco | Texas | Non ancora in reclutamento |
| Elevate Clinical Research | Wichita | Kansas | Non ancora in reclutamento |
| Delaney Radiologist | Wilmington | North Carolina | In reclutamento |
| Accellacare | Wilmington | North Carolina | In reclutamento |
| North Georgia Internal Medicine | Woodstock | Georgia | Non ancora in reclutamento |
| North Georgia Clinical Research, LLC | Woodstock | Georgia | Non ancora in reclutamento |
Documenti dello studio
In questa scheda del registro non sono collegati documenti.
Modifiche nel tempo
Non è stata registrata alcuna modifica da quando abbiamo acquisito questa scheda.
Viene registrata una modifica ogni volta che lo sponsor aggiorna la scheda del registro. Stato, date, arruolamento e centri compaiono qui man mano che cambiano.